Format

Send to

Choose Destination
Crit Rev Oncol Hematol. 2017 Oct;118:7-14. doi: 10.1016/j.critrevonc.2017.08.001. Epub 2017 Aug 14.

Cognitive impairment and chemotherapy: a brief overview.

Author information

1
Medical Oncology Department, Fondazione IRCCS Istituto Nazionale di Tumori, Milan, Italy. Electronic address: milena.vitali@istitutotumori.mi.it.
2
Supportive Care in Cancer Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
3
Medical Oncology, "S. Maria" Hospital, Terni, Italy.
4
Medical Oncology Department, Fondazione IRCCS Istituto Nazionale di Tumori, Milan, Italy.

Abstract

Patients with cancer are experiencing long-term survival following chemotherapy, but the treatment may also be associated with short and long-term toxicity, including the possibility of cognitive dysfunction. A literature overview indicated a significant association between chemotherapy and cognitive impairment but prospective longitudinal research is warranted to examine the degree and persisting nature of this decline. Although chemotherapeutic agents are unlikely to cross the blood-brain barrier, it has been alleged that the occurrence of neurotoxicity is linked to the pro-inflammatory cytokine pathways. Moreover in most cases many other factors could play an ancillary and concomitant role. The contribution of hormone therapy as well as emotional, social, behavioural and genetic factors should always be considered. Especially physical activity and cognitive training appear promising in the management of cognitive impairment but additional studies are required to establish their efficacy.

KEYWORDS:

Cancer; Chemotherapy-related toxicity; Cognitive impairment

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center